Bayer sues Lupin over generic birth control pill
FRANKFURT (Reuters) - German drugmaker Bayer (BAYGn.DE) has filed a lawsuit in the United States against Indian generic drug maker Lupin (LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia in the U.S.
In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sales of the generic product.
Lupin declined to comment on the lawsuit. "We do not comment on on-going litigations as a matter of policy," said Lupin spokesperson Shamsher Gorawara.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware. (Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle; editing by Carol Bishopric)
- Tweet this
- Share this
- Digg this
- Bighorn sheep escapes Los Angeles Zoo, dies after car strikes it
- U.S. plans to arm Iraq's Sunni tribesmen with AK-47s, RPGs, mortars
- Apple $450 mln e-book settlement gets final court approval
- China building South China Sea island big enough for airstrip - report
- Samsung files ITC complaint to block Nvidia chips from U.S. - Bloomberg
India approved on Saturday the purchase of 814 mounted gun systems for the army at a cost of 157.5 billion rupees ($2.55 billion), a defence ministry spokesman said. Full Article